Track all markets on TradingView
BioMarin’s Pipeline Faces Skepticism As Analyst Questions Future Growth
Media

BioMarin’s Pipeline Faces Skepticism As Analyst Questions Future Growth

  • October 31, 2024
  • 10 Views

BioMarin posts Q3 EPS of $0.91, nearly doubling last year’s $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Latest Ratings for BMRN

Date Firm Action From To
Feb 2022 Piper Sandler Maintains Overweight
Nov 2021 Credit Suisse Maintains Outperform
Nov 2021 Morgan Stanley Maintains Equal-Weight

View More Analyst Ratings for BMRN

View the Latest Analyst Ratings

read more

​ 

Share This Post:

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.